PositiveID accelerates prototype development of its system for real-time MDx testing

Sept. 24, 2014

Florida-based PositiveID Corporation, a developer of biological detection and diagnostics solutions, has announced that it is accelerating the prototype development of its Firefly Dx system, a handheld, real-time PCR (polymerase chain reaction) system designed to provide molecular diagnostic results in less than 20 minutes at the point of need. To advance the development, PositiveID has engaged Infinite Vision, an engineering development and contract manufacturing firm specializing in medical and biotech products.

By teaming with Infinite Vision, PositiveID expects to be able to demonstrate a bench-top prototype of the Firefly cartridge in the first half of 2015, and targets having a full handheld prototype by the end of 2015. In line with this schedule, PositiveID expects to supply testing data in 2015 that demonstrates the speed, sensitivity, and specificity of the Firefly system and ultimately positions the company for government and commercial opportunities.

Infinite Vision's product design and engineering expertise includes lab instrumentation and diagnostics, therapy delivery systems, point-of-care diagnostics, surgical tools, and microfluidics.

“To ensure the expedited development required to complete the Firefly prototype and prepare Firefly for testing by potential customers and partners, it was imperative to work with a firm like Infinite Vision, which has proven its ability to bring innovative and sophisticated products from concept to commercialization,” says William J. Caragol, Chairman and CEO of PositiveID. Read more about Firefly Dx and solutions provided by PositiveID.

Read more

Photo 103483727 © Splank | Dreamstime.com
Photo 167576138 © calypsoArt | Dreamstime.com
Photo 11175251 © Alexey Rodionov | Dreamstime.com